The medicinal role of this agent is within the therapeutic category of vasculoprotectors and venotonics. Its primary use is in the symptomatic management of conditions related to chronic circulation issues, an established therapeutic domain for this type of extract.

Endotelon is commonly used to help with symptoms related to physical discomfort associated with chronic venous insufficiency (CVI). These symptoms often cluster into patterns requiring supportive management, including aching pain, fatigue, and the persistent sensation of heavy legs. It is also relevant in conditions where symptoms are linked to specific lymphatic congestion, such as post-radiosurgical lymphedema, and is applied to help reduce pathological swelling in the lower limbs and ankles.

It offers supportive relief, contributing to easing the overall symptom load during symptomatic periods. The medication is commonly used to help manage symptoms often associated with physical strain or circulatory discomfort, including painful nocturnal muscle cramps, restless sensations, and tingling (paresthesias), assisting with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Relief for Heavy Legs

Quick Fact: Relief for Heavy Legs may be part of symptomatic management, helping to ease the chronic discomfort and fatigue associated with compromised circulation.

Regulatory References

1. Health Canada for Grape Seed Extract in CVI

Eligibility Map: Who can and cannot use Endotelon

Official regulatory documentation defines eligibility for Endotelon (Procyanidolic Oligomers) based on absolute prohibitions and restrictions for specific populations.

Eligibility Status	Population	Regulatory Classification
Must Not Use (Contraindicated)	Individuals with a known allergy to the active substance (procyanidolic oligomers) or any other component (excipients).	Contraindicated
Not Recommended	Women who are breastfeeding.	Not Recommended
Not Recommended	Children.	Not Recommended
Conditional Use	Pregnant women.	Use only on the advice of a doctor
Conditional Use	Patients with rare hereditary diseases like fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency.	Special Warning/Not Recommended

Use is contraindicated if a patient has a known hypersensitivity to the product's components. Furthermore, the medicine is not recommended for use by children due to a lack of established safety data in this age group. Use is also not recommended during breastfeeding. Due to the presence of sucrose in the formulation, a special warning applies, and use is not recommended for patients with specific hereditary sugar metabolism disorders.

Interactions with other medicines and products

Official regulatory assessments define the interaction profile of Endotelon, which contains Procyanidolic Oligomers (PCOs), primarily by timing-based administration rules and specific pharmacodynamic cautions.

Regulatory documents indicate that the product is associated with a potential for pharmacodynamic interaction when co-administered with antiplatelet or anticoagulant agents. This caution stems from in vitro effects on platelet function; however, official safety assessments note that the clinical significance of this effect in vivo is minimal due to the low systemic absorption of the active constituents.

Regarding metabolic pathways, official regulatory summaries conclude that Endotelon poses no statistically significant in vivo pharmacokinetic interaction risk through the CYP450 enzyme system, thus posing no restriction on co-administration based on metabolic modification.

Administration Restrictions:

Interacting Substance Category	Official Restriction/Condition
Live-Culture Probiotic Products	Requires separation of administration time to avoid potential reduction in the probiotic component’s efficacy.
Vitamin C	Cautionary statement for concurrent use in individuals with pre-existing hypertension.

No medicinal products are formally classified as contraindicated for co-administration in the official prescribing information reviewed.

I. Modulation of Vascular Permeability

Endotelon is a pharmacological agent that modulates vascular permeability through interaction with endothelial cell components. The primary action involves molecular interactions at the capillary endothelial layer that contribute to the stabilization of capillary wall integrity. This effect facilitates the regulation of endothelial junctional complex dynamics, thereby decreasing the width of the paracellular pathway. This results in the physiological modulation of fluid exchange, specifically a controlled reduction of fluid extravasation from the bloodstream into the interstitial space.

II. Enzymatic and Connective Tissue Interactions

A secondary mechanism of action involves the targeted modulation of enzyme activity. Endotelon acts by inhibiting the enzymatic degradation of specific connective tissue components surrounding the blood vessels. This effect alters the turnover rate of structural macromolecules, such as collagen and elastin, within the vessel wall's basement membrane and perivascular matrix. This biochemical cascade further contributes to the regulation of molecular and cellular transmigration across the capillary wall, maintaining the physiological integrity of the microvasculature.

How Endotelon is Used: Administration Guidelines

The standardized use of Endotelon follows established protocols which outline the route, dosage, frequency, and treatment cycle.

---

Administration Protocol

Feature	Instruction
Route and Form	Administered by the oral route as a 150 mg gastro-resistant coated tablet.
Dosing Schedule	The standard daily regimen is 300 mg, corresponding to two 150 mg tablets per day.
Frequency and Timing	The daily dose is taken in a divided manner (twice daily, e.g., morning and evening), and administration is recommended preferably outside of meals.

---

Procedural Conditions and Duration

The overall treatment pattern depends on the condition. For use related to venous-lymphatic support, the regimen follows a discontinuous administration cycle, typically given in courses such as 20 days per month. Conversely, use for certain lymphatic conditions requires a continuous pattern.

Missed Dose Rule: If a dose is forgotten, the standard protocol is to take the missed tablet as soon as possible and then return to the regular schedule. It is specified that a double dose must never be taken to make up for a missed one. These points establish the standardized method for taking the medicine.

Recent Clinical Evidence

Overview of Research Focus

Endotelon, a pharmaceutical product derived from grape seed extract (containing proanthocyanidolic oligomers or PCOs), has been investigated primarily for its potential role in supporting vascular health and capillary permeability. Research has explored its use in conditions related to venous and lymphatic insufficiency, where the integrity of small blood vessels is a concern.

Clinical Trials and Findings

Clinical trials have examined the effect of Endotelon on symptoms associated with chronic venous insufficiency (CVI), such as leg swelling (edema), pain, and nocturnal cramps. These studies typically use objective measures like plethysmography to evaluate changes in vascular function and subjective questionnaires to assess patient-reported symptom relief.

• Chronic Venous Insufficiency (CVI): Research has indicated that supplementation with PCOs may lead to an observed reduction in capillary permeability and fragility, which are factors contributing to CVI symptoms. Findings suggest that patients receiving the product reported some change in symptoms, particularly a decrease in the objective measurement of leg volume and edema.
• Retinopathy: Studies have also been conducted to explore Endotelon's use as an adjunct treatment in certain non-proliferative retinopathies, where fragile capillaries in the eye are a concern. Data in this area is limited, and research is ongoing to clarify any potential benefit.

Safety and Tolerability

Across clinical studies, Endotelon has generally been described as well-tolerated by participants. The most commonly reported side effects were minor and gastrointestinal in nature. Research has not indicated any significant safety concerns when the product is used as studied in the examined populations.

Common questions about Endotelon (FAQ)

Q: What is the main medical condition Endotelon is approved for?

According to official regulatory documents, Endotelon is indicated for the symptomatic treatment of chronic venous insufficiency (CVI). This medicine is classified as a vasculoprotector, which is intended to support the function and integrity of the body's small blood vessels and circulation.

The indication specifies its use to help relieve related symptoms such as feelings of heavy legs, pain, or nocturnal cramps.

Q: Can I crush the gastro-resistant tablets to make them easier to swallow?

The official administration rules state that Endotelon tablets must be swallowed whole. This medicine is designed as a gastro-resistant coated tablet, meaning the outer layer protects the active ingredient from being destroyed by stomach acid.

Crushing, chewing, or breaking the tablet is not recommended in the product information, as this action may disrupt the protective mechanism and the intended delivery of the medicine.

Q: Does Endotelon contain any sugar and should diabetics avoid it?

Yes, the formulation of Endotelon contains sucrose, which is a type of sugar. The regulatory documentation includes specific warnings related to its use in patients with rare hereditary sugar metabolism disorders.

Concerns about how this medication may affect metabolic conditions, such as diabetes, should be discussed with a healthcare professional.

How to Store and Dispose of Endotelon

Storage Requirements

Official regulatory documentation states that Endotelon (Procyanidolic Oligomers) does not require any special temperature conditions for storage, meaning it can be stored at typical ambient room temperatures.

A mandatory storage instruction for this medicine is that it must be kept out of the sight and reach of children to ensure safety and prevent accidental ingestion.

Disposal Instructions

To protect the environment, unused or expired Endotelon must not be disposed of via wastewater (such as flushing down a toilet or drain) or thrown away with ordinary household waste.

Disposal must adhere to the specific local regulatory requirements for pharmaceutical waste. This typically involves returning the product to a pharmacy or utilizing an authorized national medicine take-back program.